

**The Food and Drug Administration's Accelerated Approval Process for New Pharmaceuticals  
A Virtual Workshop**

**Planning Meeting 1**

October 28, 2022

**SPEAKER BIOGRAPHIES**

**Lovisa Gustafsson**, M.B.A., is vice president of the Controlling Health Care Costs program at the Commonwealth Fund. She joined the Fund in 2016 as the program officer for Breakthrough Health Care Opportunities and was promoted to assistant vice president in July 2018. Prior to joining the Fund, Ms. Gustafsson served as senior vice president for the Marwood Group, a health care advisory organization, where she managed various outsourced private equity due diligence and strategy consulting engagements. Before her role at the Marwood Group, she worked as a manager in corporate strategy and business development at McKesson, a senior consulting associate in quality and operations support for Kaiser Permanente, a senior policy analyst at the Commonwealth of Massachusetts Office of Medicaid, and a manager at Avalere Health LLC. Ms. Gustafsson earned an M.B.A. in health care management from the Wharton School at the University of Pennsylvania and a B.A. in sociology from Harvard University.

**Krysten Joyce** is a senior health policy consultant in the Institute for Health Policy at Kaiser Permanente. In her role, Joyce provides content and strategy expertise to organization's drug pricing and coverage initiatives. She also conducts research, tracks policy developments, and facilitates conversations among internal and external experts in the field. She is currently particularly focused on fair drug pricing policy and vaccine development. Other topics she tracks include universal coverage policy, affordability, and delivery system reform.

Prior to joining Kaiser Permanente, Joyce served as Strategy and Policy Manager at the Colorado State Innovation Model, a federally funded initiative under the Governor's office, where she identified policy strategies to improve access to integrated physical and behavioral health and led state efforts to explore development of new alternative payment models. Before that, she served as the health care staffer for U.S. Senator Mark Udall (D-CO), advising on issues including the Affordable Care Act, women's reproductive health, and rural health services.

Joyce holds a bachelor's degree and a master of public health degree in health policy and management from the University of California, Berkeley.

**Katherine Szarama** is Director of Health Care - Drug Pricing at Arnold Ventures where she develops and oversees strategic investments to help lower health care spending, particularly drug costs, as part of the Health Care team. Her work includes identification of investment opportunities to increase transparency in clinical trials and improve the quality of regulatory drug review.

With her experience, Szarama identifies emerging regulatory and reimbursement issues for high-cost drugs, devices, and biologics. Previously, she advanced Coverage with Evidence Development policies as part of writing National Coverage Determinations for the Centers for Medicare & Medicaid Services. For this work, Szarama was recognized by both CMS Administrator and FDA Commissioner with awards for outstanding service. To complement this experience, Szarama served as research and venture grants manager for Reed Jobs and the Health Team at Emerson Collective, a social change organization established and led by Laurene Powell Jobs focused on advancing immigration reform, reimagining the future of high school, seeking an end to gun violence in Chicago, championing environmental justice, and accelerating cancer research and treatments. Specifically, Szarama partnered with leading, cutting-edge researchers and innovative entrepreneurs to help transform groundbreaking scientific discoveries into potentially groundbreaking treatments for patients with significant unmet needs.

Szarama completed her fellowship in cancer biology at St. Jude Children's Research Hospital. She earned degrees from Johns Hopkins University and Karolinska Institutet as part of an intramural neuroscience research program with the National Institutes of Health.